CytoDyn Inc.
CytoDyn Inc. is a clinical-stage biotechnology company focused on developing leronlimab (PRO 140), a humanized monoclonal antibody that targets CCR5. The company is pursuing the drug candidate across multiple therapeutic areas, with current emphasis on solid-tumor oncology, while also exploring a longer-acting modified therapeutic through a joint development effort.
Tilikausi 2026 · muutos edellisvuodesta
Kehitys 2021–2026
Liiketoiminta
Osuus liikevaihdostaDevelopment of the company’s lead CCR5-targeting antibody for multiple therapeutic indications.
Joint development work aimed at creating a modified, longer-acting version of the molecule.
Internal and outsourced R&D, testing, and regulatory work supporting the drug candidate.
Asiakkaat
CytoDyn does not currently sell commercial products; its primary “customers” are future patients, physicians, and regulators that must support approval of leronlimab. In the near term, the company’s operational counterparties are CROs, CMOs, consultants, and development partners that provide trial execution, manufacturing, and discovery support.
Would receive leronlimab if approved; the company is developing the drug for solid-tumor oncology and other potential uses.
Influence trial design, adoption, and eventual prescribing if the product reaches market.
FDA and other agencies review safety, efficacy, manufacturing, and labeling before commercialization.
Buy development work, trial execution, and manufacturing services to support the pipeline.
Strategia
CytoDyn’s strategy is to advance leronlimab through additional clinical work, secure regulatory approval, and eventually commercialize the asset if data support it. The company is also trying to extend the platform through a longer-acting CCR5 antagonist collaboration, while relying on external financing and third-party development infrastructure to conserve internal resources.
Approval depends on generating sufficient safety and efficacy data.
The company is a going concern and needs capital to fund operations.
A modified molecule could improve patient convenience and extend IP value.
Maantiede
CytoDyn is headquartered in Vancouver, Washington and operates as a U.S.-based clinical-stage biotech. The company seeks patent protection selectively in the U.S., Canada, China, Japan, and European Patent Convention countries, reflecting a broad potential commercialization footprint even though it currently has no revenue-producing operations.
Riskit
CytoDyn is highly dependent on successful clinical outcomes, regulatory approval, and third-party execution, while having no product revenue to offset development spending. Its financing needs, litigation exposure, and reliance on external manufacturers and CROs create substantial execution and liquidity risk.
- Going concern and capital dependenceVaikutus: KriittinenTodennäköisyys: Korkea
The company has no revenue and must raise additional capital to fund operations and trials.
Kohdistuu - Clinical development failureVaikutus: KriittinenTodennäköisyys: Korkea
Leronlimab is the core asset; weak efficacy or safety data would impair approval prospects.
Kohdistuu - Regulatory and legal proceedingsVaikutus: KorkeaTodennäköisyys: Korkea
FDA/SEC oversight and litigation can divert management and increase costs.
Kohdistuu - Third-party manufacturing and CRO dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
The company relies on external partners for trials, GMP supply, fill-finish, and packaging.
Kohdistuu - Intellectual property protectionVaikutus: KorkeaTodennäköisyys: Kohtalainen
Value depends on maintaining patent coverage and defending ownership or infringement claims.
Kohdistuu: Leronlimab and future modified molecules
Kirjanpito
Harkinnanvaraiset erätManagement must judge whether available cash and financing plans are sufficient to continue operations.
Vaikutus: Can affect audit opinion, disclosure tone, and investor perception
Equity awards are a meaningful expense for a small development-stage company.
Vaikutus: Affects G&A and R&D expense trends
Financing instruments may create non-cash interest, derivative, or modification charges.
Vaikutus: Can distort period-to-period comparability
Clinical employee compensation was reclassified into R&D in the current year.
Vaikutus: Changes the mix between R&D and G&A without changing total cash burn
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
CytomX Therapeutics, Inc.
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
aTyr Pharma, Inc
ATYR · Biological Products, (No Diagnostic Substances)
aTyr Pharma is a U.S.-based biotechnology company focused on discovering and developing protein-based therapeutics derived from tRNA synthetase biology.
Cytosorbents Corp
CTSO · Surgical & Medical Instruments & Apparatus
Cytosorbents Corp develops blood purification and adsorption devices used in critical care, cardiac surgery, and other acute care settings.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
YD Bio Ltd
YDES · Services-Medical Laboratories
YD Bio Ltd is a U.S.-anchored biotechnology and medical-laboratory services company with operations spanning regulated diagnostics, life science clinical…
Sigyn Therapeutics, Inc.
SIGY · Surgical & Medical Instruments & Apparatus
Päivitetty: 24.9.2026